menu
    • menu

    Company profile for Chrysalis BioTherapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    ChrysalisBioTherapeutics, Inc. is a privately held biopharmaceutical company developing regenerative drugs that mimic the body’s natural signals to activate endothelial progenitor cells and stem cells to stimulate tissue repair and restore normal tissue function. Chrysalis BioTherapeutics was incorporated in Delaware in 2012 to develop innovative peptide therapeutics to save lives and improve life’s quality. Chrysalis’ l...
    ChrysalisBioTherapeutics, Inc. is a privately held biopharmaceutical company developing regenerative drugs that mimic the body’s natural signals to activate endothelial progenitor cells and stem cells to stimulate tissue repair and restore normal tissue function. Chrysalis BioTherapeutics was incorporated in Delaware in 2012 to develop innovative peptide therapeutics to save lives and improve life’s quality. Chrysalis’ lead drug candidate, TP508, was initially developed to accelerate healing of dermal and musculoskeletal injuries.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Chrysalis BioTherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2200 Market Street, STE 609 Galveston, TX 77550
    Telephone
    Telephone
    409-497-4083
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://chrysbio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/chrysalis-biotherapeutics/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/chrysbioTX

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Chrysalis Collaborates with NIAID on Chrysalin for Radiation Injury
    Chrysalis Collaborates with NIAID on Chrysalin for Radiation Injury

    18 Nov 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241118314186/en

    BUSINESSWIRE
    18 Nov 2024
    Share Share
    Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit
    Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit

    06 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240506556298/en

    BUSINESSWIRE
    06 May 2024
    Share Share
    Chrysalis Receives FDA Approval to Initiate Trials with Chrysalin™ (TP508)
    Chrysalis Receives FDA Approval to Initiate Trials with Chrysalin™ (TP508)

    26 Sep 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230926039273/en

    BUSINESSWIRE
    26 Sep 2023
    Share Share
    Intouch Group Launches Pro-Bono Alliance with The Chrysalis Initiative
    Intouch Group Launches Pro-Bono Alliance with The Chrysalis Initiative

    05 Oct 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/intouch-group-launches-pro-bono-alliance-with-the-chrysalis-initiative-to-shed-light-on-biased-healthcare-system-301392479.html

    PRNEWSWIRE
    05 Oct 2021
    Share Share
    Chrysalis Receives $10.4 M From BARDA to Continue Development of TP508
    Chrysalis Receives $10.4 M From BARDA to Continue Development of TP508

    01 Dec 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201201005171/en

    BUSINESSWIRE
    01 Dec 2020
    Share Share
    Chrysalis BioTherapeutics Receives $10.4 Million From BARDA
    Chrysalis BioTherapeutics Receives $10.4 Million From BARDA

    01 Dec 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20201201005171/en/Chrysalis-BioTherapeutics-Receives-10.4-Million-From-BARDA-to-Continue-Development-of-TP508-as-a-Nuclear-Countermeasure

    BUSINESSWIRE
    01 Dec 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search